Accelerate Product Release with Rapid Sterility Testing

Is your sterility testing strategy slowing down product release?

Traditional USP <71> sterility testing has long been the industry standard, but its 14-day incubation period can create bottlenecks in manufacturing timelines and delay product release. For companies working with time-sensitive therapies and complex pharmaceutical products, faster solutions are increasingly critical.
Explore how ATP-bioluminescence rapid sterility testing compares with traditional USP <71> methods and learn how accelerated testing approaches may help improve operational efficiency while maintaining quality and compliance.

What You’ll Learn:

• Key differences between traditional USP <71> sterility testing and ATP-bioluminescence rapid methods
• How rapid testing can deliver results in as little as 6 days compared to the traditional 14-day incubation period
• Advantages, limitations and validation considerations for each approach
• Regulatory and implementation factors to consider when evaluating rapid sterility methods
• How Cambrex supports clients in selecting the right sterility testing strategy for their products

Whether you’re developing biologics, injectable products or advanced therapies with short shelf lives, understanding your sterility testing options can help you make informed decisions that impact timelines, resources and product availability. Download the information sheet and gain the insights you need to evaluate faster sterility testing approaches and support more efficient pharmaceutical development and manufacturing decisions.